Compare TVRD & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TVRD | XLO |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | TVRD | XLO |
|---|---|---|
| Price | $4.37 | $0.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $51.67 | $2.00 |
| AVG Volume (30 Days) | 109.7K | ★ 423.1K |
| Earning Date | 02-21-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $3.74 | $0.57 |
| 52 Week High | $43.65 | $1.70 |
| Indicator | TVRD | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 38.75 |
| Support Level | $4.39 | $0.57 |
| Resistance Level | $4.89 | $0.65 |
| Average True Range (ATR) | 0.31 | 0.04 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 43.63 | 24.33 |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.